Piper Sandler analyst Matt O’Brien initiated coverage of Beta Bionics (BBNX) with an Overweight rating and $26 price target The company has a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback